FBN features Prescient Medical's CEO

Prescient Medical Inc. announced that CEO Patricia Scheller, appeared on FOX Business Network (FBN) to discuss the company's groundbreaking products and recent achievement of CE Mark approval for their vProtect(TM) Luminal Shield Stent System.

"The FOX Business News appearance is an important recognition of the increasing awareness of cardiovascular disease," stated Ms. Scheller. Each year, approximately 1.5 million Americans will have a heart attack and 650,000 will not survive, making it the leading cause of death in the US. It is estimated that the costs associated with treating heart attacks in the US are over $80 billion per year, or approximately $54,000 per patient, according to 2007 statistics. In addition to the significant financial expenses, the societal and personal costs of the disease are also substantial. "Our goal at Prescient is to ultimately provide the world's first products to stop heart attacks before they happen," she continued.

Ms. Scheller was featured on the "C-Suite Sit-Down" segment on Monday, August 24, 2009, broadcast at 6:40 AM (EDT) in the United States.

Prescient Medical was founded to commercialize a pioneering suite of diagnostic technologies and protective solutions for people with cardiovascular disease. The Company's mission is to reduce morbidity and mortality from heart attacks. Prescient's product portfolio includes catheter-based devices that will allow interventional cardiologists to more precisely tailor focal treatment according to the unique needs of each patient.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
GLP-1 and SGLT2 inhibitors show promise in preventing recurrent stroke and heart attack